The kind of data oncologists need to move towards value-based care isn’t easily accessible in patient electronic health records, but new platforms like Cancer Outcomes Tracking and Analysis (COTA) are trying to make it easier, said Stuart Goldberg, MD, chief medical officer, COTA, John Theurer Cancer Center.
The kind of data oncologists need to move towards value-based care isn’t easily accessible in patient electronic health records, but new platforms like Cancer Outcomes Tracking and Analysis (COTA) are trying to make it easier, said Stuart Goldberg, MD, chief medical officer, COTA, John Theurer Cancer Center.
Transcript (slightly modified)
How do you predict the COTA data analysis platform will shape the future of oncology reform?
We’re in an era where we’re moving toward value-based programs, as opposed to volume-based, and part of the idea of value is to divide the outcomes by the cost. Well, in order to do that, you have to understand what you’re actually seeing, group them properly, and then understand the costs. Most oncologists couldn’t tell you how many patients they see with breast cancer, no less how many patients have HER2/neu breast cancer or stage IV breast cancer. That’s not easily accessible in the electronic health records.
So what COTA has done is try to organize the patients in a way that makes oncologic sense, so that we can then give that information back to the insurance carriers, and to the practices, and even make it available to the public. Once that data’s out there, we can then do big data analytics to then drive the value equation and help with payment reform.
The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret
October 22nd 2024In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.
Read More
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
A Novel Approach to Chronic GVHD With Axatilimab: Dr Daniel Wolff
October 18th 2024The latest therapy approved to treat chronic graft-versus-host disease (GVHD) has a new target different than the other approved therapies. Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier.
Read More